NewsRelease
ResearchArticle Cites Cleanascite™ To Study Lipid Metabolism in Cancer
MONMOUTHJUNCTION, NJ,August6, 2019 -- Biotech Support Group reports on a recent research articledescribing the simplicity and efficiency of their lipid clearancesample preparation technology for studying cell response associatedwith peritonealmetastases in ovarian cancer cells.The citation is:
Chen,Rain R., et al. "Targetingof lipid metabolism with a metabolic inhibitor cocktail eradicatesperitoneal metastases in ovarian cancer cells." CommunicationsBiology 2(2019).
Ovariancancer is an intra-abdominal tumor in which the presence of ascitesfacilitates metastatic dissemination, and is associated with poorprognosis. However, the significance of metabolic alterations inovarian cancer cells in the ascites microenvironment remains unclear.In this study, the authors investigated whether reprogramming oflipid metabolism in ovarian cancer cells could modulate cellviability and aggressiveness. The article states: ”To determinewhether fatty acids in OCM are the primary energy source, fatty acidsfrom OCM was first removed by Cleanascite™ Lipid Removal Reagent...Then, XTT cell proliferation assays showed that the growth rate ofovarian cancer cells was remarkably reduced in cells cultured inCleanascite-treated OCM. Likewise, co-treatment with Cleanascite andOCM significantly attenuated the increased cell migration andinvasion capacities of ES-2 and SKOV3 cells. These findings suggestthat the fatty acid-enriched OCM provides as an energy source forsupporting tumor growth and aggressiveness of ovarian cancer cells.”.The authors conclude that targetingthe lipid metabolism signaling axis impedes ovarian cancer peritonealmetastases.
“Iam pleased that using Cleanascite™ helped to identify fatty acidsas a mediator of cancer cell response. This demonstrates theadvantage of using an aqueous suspension product with no harmfulsolvents, so one can challenge cells for responsiveness. Thisultimately helps researchers decide whether a lipid factor is or isnot consistent with cancer growth and metastatic potential. Wehighlight many such cell response references in our recentlypublished whitepaper.” states Swapan Roy, Ph.D., President andFounder of Biotech Support Group.
Todownload whitepaper entitled “Cleanascite™- Lipid Removal and Cell Response Applications”,visit:
Formore information visit: Cleanascite™Lipid Removal Reagent and Clarification,at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NuGel™ for functional proteomics. From these innovations, thecompany has acquired knowledgebase and biomarker intellectualproperty assets that support discoveries of protein markers fromblood, with special emphasis on early detection and personalizedmedical decisions for cancer patients. For more information, go tohttp://www.biotechsupportgroup.com/.
Contact:MatthewKuruc 732-274-2866, [email protected]